TCDB is operated by the Saier Lab Bioinformatics Group

8.C.2 The Talatisamine (Talatisamine) Family 

Loss of cytosolic K+ through up-regulated delayed rectifier K+ channels plays a protective role against beta-amyloid (Aβ) induced neurotoxicity. Potent K+ channel blockers, specific for I(K) channels, are candidates for Alzheimer's disease (AD) treatment. Talatisamine is a I(K) channel blocker. Wang et al. (2012) examined the neuroprotective effect of talatisamine against Aβ oligomer-induced cytotoxicity in primary cultured cortical neurons. The neurotoxicity related to K+ loss caused by Aβ40 oligomers included enhanced I(K) density, increased cell membrane permeability, reduced cell viability, and an impaired mitochondrial transmembrane potential. Decreased Bcl-2 and increased Bax levels, activation of Caspase-3 and Caspase-9 were also observed after Aβ40 oligomer incubation. Talatisamine (120μM) inhibited the enhanced I(K) caused by Aβ40 oligomers, attenuated cytotoxicity of Aβ oligomers by restoring cell viability and suppresed K+-loss-related apoptotic responses (Wang et al., 2012).

References associated with 8.C.2 family:

Wang Y., Song M., Hou L., Yu Z. and Chen H. (2012). The newly identified K+ channel blocker talatisamine attenuates beta-amyloid oligomers induced neurotoxicity in cultured cortical neurons. Neurosci Lett. 518(2):122-7. 22561032